R&D Trends

Janssen, Hanmi ink diabetes and obesity agreement

Wednesday, November 11, 2015

Janssen Pharmaceuticals has obtained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based therapies including HM12525A, a biologic that is completing phase I and expected to enter phase II studies next year, from Hanmi Pharmaceutical. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.

[Read More]

Orphan drugs cost 13.8 times more per patient

Thursday, November 5, 2015

With 2020 worldwide sales forecast at $178 billion, the orphan drug market is expected to grow by 11.7% per year (CAGR 2015 to 2020), nearly doubling the yearly growth of the overall prescription drug market. Moreover, worldwide orphan drug sales will account for 20.2% of worldwide prescription sales by 2020 (excluding generics) according to the “EvaluatePharma Orphan Drug Report 2015” from life science market intelligence firm Evaluate.

[Read More]

NIH awards City of Hope $2.2M grant

Thursday, November 5, 2015

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) has awarded a $2.2 million grant to help City of Hope researchers explore the underlying mechanisms of graft-versus-host disease, the leading cause of long-term sickness and death following transplantation of bone marrow cells from a donor. The grant, awarded to Defu Zeng, M.D., a professor of diabetes immunology and hematopoietic cell transplantation at the Beckman Research Institute of City of Hope, will be used by researchers to study the interactions of immune cells known as T cells and B cells during the development of GVHD.

[Read More]

San Antonio’s cancer genomics partnership launches

Wednesday, November 4, 2015

The San Antonio 1000 Cancer Genomes Project (SA1kCGP), Shanghai-based WuXi NextCODE and South Texas Accelerated Research Therapeutics (START) have partnered to enable San Antonio’s pioneering citywide cancer genomics effort to contribute directly to improving the clinical treatment of cancer around the globe. The SA1kCGP brings together hundreds of doctors, oncologists and surgeons, and a thousand patients to create the basis for the resource: tumor samples from breast, lung, prostate, skin, colorectal, uterine, pancreatic, ovarian, stomach, brain cancers, collected at the time of diagnosis.

[Read More]

Sanofi, BioNTech ink cancer immunotherapy agreement

Wednesday, November 4, 2015

BioNTech, a Mainz, Germany-based immunotherapy provider, have entered into a multiyear exclusive collaboration and license agreement to leverage the scientific expertise of the two organizations to discover and develop up to five cancer immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).

[Read More]